protein

Alpha-synuclein Blocking Peptide

MBS8227982

1 mg

160 USD

Blocking Peptide

Alpha-synuclein Blocking Peptide

[Alpha-synuclein]

[NACP; PARK1; Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP]

[alpha-synuclein isoform NACP140; Alpha-synuclein; alpha-synuclein; synuclein, alpha (non A4 component of amyloid precursor); Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP]

[SNCA]

[SNCA; SNCA; PD1; NACP; PARK1; PARK4; NACP; PARK1; NACP]

SYUA_HUMAN

Human, Mouse, Rat, Monkey

126

>85%

Lyophilized powder

Shipped at 4 degree C. Store at -20 degree C for one year.

Blocking (BL)

Source: Synthetic

Quality Control: The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. Directions for Use: Blocking Peptide to the diluted primary antibody in a molar ratio of 10:1 (peptide to antibody) and incubate the mixture at 4 degree C for overnight or at room temperature for 2 hours.

The peptide is used to block Anti-Alpha-synuclein Antibody reactivity.

4507109

NP_000336.1

NM_000345.3

P37840

13,109 Da

Alpha-synuclein Signaling Pathway (137913); Alzheimer's Disease Pathway (83097); Alzheimer's Disease Pathway (509); Alzheimers Disease Pathway (672448); Amyloids Pathway (1269169); Disease Pathway (1268854); EGFR1 Signaling Pathway (198782); Parkin-Ubiquitin Proteasomal System Pathway (700638); Parkinson's Disease Pathway (83098); Parkinsons Disease Pathway (705377)

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene. [provided by RefSeq, Mar 2009]

SNCA: a member of the synuclein family. Abundantly expressed in the brain. Inhibits phospholipase D2 selectively. May integrate presynaptic signaling and membrane trafficking. Implicated in the pathogenesis of Parkinson s disease. A major component of amyloid plaques in the brains of patients with Alzheimer s disease. Two alternatively spliced isoforms transcripts have been identified. Protein type: Adaptor/scaffold. Chromosomal Location of Human Ortholog: 4q21. Cellular Component: Golgi apparatus; nuclear outer membrane; rough endoplasmic reticulum; mitochondrion; lysosome; extracellular region; fibril; terminal button; inclusion body; cell cortex; mitochondrial respiratory chain complex I; cytosol; actin cytoskeleton; platelet alpha granule membrane; synaptic vesicle; growth cone; axon; perinuclear region of cytoplasm; cytoplasm; plasma membrane; ribosome; cell junction; nucleus. Molecular Function: protein domain specific binding; identical protein binding; zinc ion binding; histone binding; kinesin binding; microtubule binding; ferrous iron binding; caspase inhibitor activity; magnesium ion binding; beta-tubulin binding; protein N-terminus binding; phosphoprotein binding; Hsp70 protein binding; oxidoreductase activity; calcium ion binding; dynein binding; protein binding; copper ion binding; phospholipase binding; phospholipid binding; fatty acid binding; tau protein binding; alpha-tubulin binding. Biological Process: regulation of acyl-CoA biosynthetic process; adult locomotory behavior; positive regulation of apoptosis; response to lipopolysaccharide; positive regulation of endocytosis; dopamine biosynthetic process; positive regulation of neurotransmitter secretion; calcium ion homeostasis; response to magnesium ion; synapse organization and biogenesis; fibril organization and biogenesis; dopamine uptake; negative regulation of neuron apoptosis; response to drug; negative regulation of dopamine metabolic process; synaptic vesicle endocytosis; negative regulation of transporter activity; negative regulation of apoptosis; regulation of long-term neuronal synaptic plasticity; negative regulation of serotonin uptake; mitochondrial membrane organization and biogenesis; negative regulation of norepinephrine uptake; microglial cell activation; negative regulation of monooxygenase activity; negative regulation of transcription from RNA polymerase II promoter; negative regulation of caspase activity; fatty acid metabolic process; regulation of dopamine secretion; negative regulation of dopamine uptake; negative regulation of histone acetylation; negative regulation of exocytosis; negative regulation of protein amino acid phosphorylation; behavioral response to cocaine; receptor internalization; phospholipid metabolic process; response to iron(II) ion; positive regulation of receptor recycling; aging; caspase activation; neutral lipid metabolic process; protein destabilization; negative regulation of microtubule polymerization; regulation of macrophage activation; regulation of glutamate secretion; positive regulation of peptidyl-serine phosphorylation; organelle ATP synthesis coupled electron transport; regulation of locomotion; positive regulation of release of sequestered calcium ion into cytosol; regulation of excitatory postsynaptic membrane potential. Disease: Parkinson Disease 4, Autosomal Dominant; Dementia, Lewy Body; Parkinson Disease 1, Autosomal Dominant

1 mg

160 USD

5 mg

305